Evotec SE Logo

Evotec SE

A drug discovery and development partner for pharma, biotech, and academia.

EVT | F

Overview

Corporate Details

ISIN(s):
DE0005664809 (+1 more)
LEI:
529900F9KI6OYITO9B12
Country:
Germany
Address:
Essener Bogen 7, 22419 Hamburg
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Evotec SE is a life science company that provides drug discovery and development solutions to pharmaceutical and biotechnology companies, as well as academic institutions. The company offers a fully integrated research and development value chain, leveraging proprietary technology platforms and deep disease understanding to accelerate the creation of new medicines. Its expertise spans multiple therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics subsidiary, the company also provides advanced solutions for the design, development, and manufacturing of biologics. Evotec operates through flexible partnership models, aiming to enhance the speed, efficiency, and quality of bringing novel treatments to patients.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-03 13:28
Regulatory Filings
Release according to Article 41 of the WpHG [the German Securities Trading Act]…
English 4.9 KB
2025-11-28 11:23
Declaration of Voting Results & Voting Rights Announcements
English 16.6 KB
2025-11-24 10:39
Declaration of Voting Results & Voting Rights Announcements
English 16.9 KB
2025-11-17 15:27
Transaction in Own Shares
Release of a capital market information
English 8.2 KB
2025-11-14 16:14
Director's Dealing
Evotec SE: Dr. Cord Dohrmann, sell
English 6.1 KB
2025-11-13 13:19
Director's Dealing
Evotec SE: Wesley Wheeler, buy
English 6.0 KB
2025-11-12 07:30
Regulatory Filings
Evotec receives milestone payment from Bristol Myers Squibb following IND accep…
English 14.5 KB
2025-11-06 15:35
Transaction in Own Shares
Release of a capital market information
English 6.2 KB
2025-11-06 00:00
Quarterly Report
Q3 statement / Q3 financial report 2025
English 296.9 KB
2025-11-05 07:30
Earnings Release
Evotec SE reports 9M 2025 results: Continued strong execution on strategic prio…
English 19.0 KB
2025-11-04 22:05
M&A Activity
In a landmark industry transaction, Evotec signs agreement with Sandoz, resulti…
English 15.8 KB
2025-10-29 09:45
Report Publication Announcement
Evotec SE to announce results for the first nine months 2025 on 05 November 2025
English 11.5 KB
2025-10-27 07:30
Regulatory Filings
Evotec announces progress in preclinical neuroscience partnership with Bristol …
English 11.5 KB
2025-10-23 09:36
Declaration of Voting Results & Voting Rights Announcements
Release according to Article 41 of the WpHG [the German Securities Trading Act]…
English 4.7 KB
2025-09-16 12:07
Director's Dealing
Evotec SE: Paul Hitchin, buy
English 5.9 KB

Automate Your Workflow. Get a real-time feed of all Evotec SE filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Evotec SE

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Evotec SE via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-02-06 Dohrmann, Dr. Cord Board Other None 91,363.32 EUR
2024-10-01 Rouxel, Laetitia Board Other None 58,396.84 EUR
2024-09-13 Wojczewski, Dr. Christian Board Buy None 61,087.50 EUR
2024-09-05 Dalbiez, Aurélie Board Buy None 21,202.55 EUR
2024-09-02 Wojczewski, Dr. Christian Board Buy None 64,466.00 EUR
2024-08-29 Löw-Friedrich, Prof. Dr. Iris Supervisory board Buy None 100,050.00 EUR
2024-08-23 Wojczewski, Dr. Christian Board Buy None 113,291.94 EUR
2024-08-22 Johnstone, Dr. Craig Board Buy None 16,553.03 EUR
2024-08-19 Wojczewski, Dr. Christian Board Buy None 59,766.00 EUR
2024-05-03 Dohrmann, Dr. Cord Board Other None 76,220.10 EUR

Peer Companies

Rafael Holdings, Inc. Logo
Invests in and develops novel therapeutics for cancer and rare diseases.
United States of America
RFL
Rain Enhancement Technologies Holdco, Inc. Logo
Develops ionization tech to generate rain and mitigate fog for water-scarce regions.
United States of America
RAIN
Rallybio Corp Logo
Develops therapies for severe and rare diseases in hematology and complement dysregulation.
United States of America
RLYB
RaQualia Pharma Inc. Logo
An R&D firm discovering novel small molecules for out-licensing to pharma partners.
Japan
4579
RECURSION PHARMACEUTICALS, INC. Logo
AI-driven biotech accelerating drug discovery for rare diseases and oncology.
United States of America
RXRX
RELMADA THERAPEUTICS, INC. Logo
A clinical-stage biotech developing novel therapies for CNS diseases and oncology.
United States of America
RLMD
RenovoRx, Inc. Logo
Develops a device platform for delivering targeted therapies directly to solid tumors.
United States of America
RNXT
Repare Therapeutics Inc. Logo
Develops precision oncology drugs using a CRISPR platform for cancers with genomic instabilities.
United States of America
RPTX
Replimune Group, Inc. Logo
Clinical-stage biotech developing oncolytic immunotherapies to treat a broad range of cancers.
United States of America
REPL
ReproCELL Incorporated Logo
Offers stem cell tech, gene editing & drug discovery services for preclinical/clinical research.
Japan
4978

Talk to a Data Expert

Have a question? We'll get back to you promptly.